• Administration of donor-specific regulatory T cells prevents chronic rejection of bonemarrow and skin allografts in the mouse • Injected regulatory T cells induce the emergence of host regulatory T cells with similar specificity, thus ensuring persistence of tolerance
Introduction
Transplantation of allogeneic tissue and organs is severely hindered by the vigorous reaction of the host's immune system to the foreign graft. Unless inhibited by immunosuppressive drugs, this alloreactivity leads to rapid rejection. However, these medicaments do not prevent chronic allograft rejection. Moreover, the induced paralysis of the immune system explains the increased incidence of cancer and opportunistic infections. The life-long use of drugs is also associated with direct toxic side effects. Means to prevent chronic allograft rejection should therefore be developed 1, 2 .
Despite the random nature of the somatic rearrangements that determine the antigenspecificity of developing T lymphocytes, these cells normally do not attack self-tissues.
Several mechanisms are involved in this self-tolerance 3, 4 . For example, developing autospecific T cells die upon recognition of their peptide/MHC ligand expressed by thymic dendritic cells. Indeed, the T cell repertoire developing in mice in which thymic dendritic cells do not express MHC molecules is strongly autoreactive in vitro and in vivo [5] [6] [7] [8] . Some autospecific T cells nevertheless escape to the periphery 9, 10 . These cells are kept under control by regulatory T cell (Treg)-populations. The most extensively studied Treg express the co-receptor CD4 and Foxp3. Patients and mice carrying mutations in the gene encoding this forkhead/winged helix transcription factor rapidly develop a lethal autoimmune syndrome, best illustrating the central role of Treg in the control of autospecific lymphocytes [11] [12] [13] . Selftolerance is therefore maintained by at least two important mechanisms: deletion and regulation. Induction of genuine tolerance to donor-antigens therefore presumably also needs these two mechanisms.
Seminal work by Medawar and colleagues showed that congenital hematopoietic chimerism strongly favors acceptance of skin grafts of the same donor 14 . Deletion of autospecific T cells presumably played a major role in this phenomenon. However, unless chimerism induced Treg, which has never been shown, it appears unlikely that it will lead to full tolerance to the skin grafts. Indeed, despite the substantial delay in acute rejection, chronic rejection is not prevented by hematopoietic chimerism (reviewed in ref. 15 ). We and others therefore assessed the capacity of Treg to induce long-lasting transplantation tolerance in the mouse.
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When these hematopoietic chimeras were grafted with skin or heart from the same donor, transplants survived for at least 100 days and chronic rejection was fully prevented. The combination of hematopoietic chimerism and Treg of appropriate specificity, therefore, appeared to ensure full tolerance to the grafts 18 . Separately, these two approaches also strongly favor acceptance of allografts 19, 20 , but best results were obtained by associating them.
Whereas, in absence of rejection, hematopoietic chimerism is maintained by self-renewing stem cells, little is known about the life expectancy of administered Treg. When injected into mutant animals in which production of Treg is impaired, Treg can persist over prolonged periods 21 . In our earlier work we showed that injected Treg survived substantially longer in presence of hematopoietic cells for which they were specific than in their absence 18 .
However, nine weeks after injection their representation in the blood had dropped substantially and it was unclear if these cells would home to tissues or entirely disappear. It was therefore important to assess if persistence of administered Treg is required for long-term maintenance of tolerance to the graft. We here address this issue by first quantifying the persistence of injected Treg in different tissues. We then actively eliminated these cells in vivo and monitored survival of BM and skin allografts. Given that we observed that injected Treg become dispensable for persistent tolerance to the grafts, we also investigated mechanisms involved in the long-term prevention of chronic rejection.
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Methods

Mice
Mice were purchased from the Centre de Recherche et d'Elevage Janvier (Le Genest St.
Isle, France). C57BL/6 (B6) Thy1.1 and DEREG mice 22 were bred in our animal facility. All experiments involving animals were performed in compliance with relevant laws (authorization # 31 09 555 45) and institutional guidelines and were approved by the ethics committee (MP/01/40/11/06).
Antibodies
Blue (RM4-5); αCD8-Pacific Blue (53.6.7); αCD3-Pacific Orange (500A2); αCD25-APC (PC61); αVβ3, Vβ4, Vβ5, Vβ6 and Vβ14-biotin (BD Biosciences, Heidelberg, Germany); αNK-FITC (DX5); αCD4-PECy7 (GK1.5); αThy1.1-APC (HiS51) and αB220-APC (RA3-6B2); αCD25-PE (PC61.5); purified F4/80 (BM8) and αFoxp3 mAb (FJK-16s); Streptavidin-eFluor710 (eBioscience, San Diego, CA). Hybridoma supernatants of αFcγRII/III (2.4G2), αCD8 (53.6.7), αMHC class II (M5/114.15.2), and αThy1.2 (AT83).
Purification and in vitro culture of CD4 + CD25 + Treg
CD4 + CD25 + splenic T cells were purified and cultured with γ-irradiated splenocytes as previously described 16 . Cell purity was checked by flow-cytometry on a FACSCalibur (BD Bioscience, San Jose, CA) and was routinely ≥ 95%.
BM and skin transplantation
Skins and T-cell depleted BM were transplanted as previously described 18 . Skins were considered rejected if ≥ 70% of the surface was necrotic.
In vivo depletion of Treg
Chimeras were IP injected with 1.5μg Diphtheria Toxin (Sigma-Aldrich, St Quentin Fallavier, France) diluted in PBS on two consecutive days.
Flow cytometry
Cell suspensions were stained using saturating concentrations of antibody. Acquisition was performed on an LSRII or a FORTESSA cytometer (Becton Dickinson, Franklin Lakes, US) and data were analyzed using FlowJo software (Tree Star, Ashland OR).
Histological analysis
Skin biopsies were fixed in 10% buffered formalin and embedded in paraffin. Sections were stained as indicated. F4/80 and αFoxp3 antibody binding was revealed using αrat Ig-biotin (DAKO, Denmark) and streptavidine-HRP (Vector laboratories, Berlingame, CA).
Statistical analysis
Statistical significance was determined by using Student's t-test with Bonferroni correction.
Results
Administered Treg wane away with time
We previously showed that donor-specific Treg durably prevented rejection of semi and fully allogeneic BM allografts 16 . To assess if administered Treg need to persist to maintain tolerance to the donor, we set up an experimental system in which Treg can be deleted in vivo. DEREG mice carry a transgenic BAC construct in which the Foxp3-promoter drives expression of the Diphtheria Toxin Receptor (DTR) and enhanced green fluorescent protein (eGFP) 22 . Practically all CD4 + CD25 high Treg in C57BL/6 (B6) DEREG mice therefore express eGFP ( Fig. 1A ). We isolated CD4 + CD25 high cells from spleens of transgenic animals ( For personal use only. on November 1, 2017. by guest www.bloodjournal.org From
Diphtheria toxin-mediated in vivo depletion of Treg
These data therefore suggested that persistence of injected donor-specific Treg is not required for maintenance of tolerance to the BM allograft. However, at 70 days after injection, a very small number of DEREG Treg still remained detectable, especially in BM ( Fig. 1F ).
Therefore, we cannot formally conclude that administered Treg do no longer play a role in protection of the graft. To directly address this question, we next depleted administered DEREG Treg by injection of diphtheria toxin. Preconditioned wt B6 mice were grafted with CBA bone marrow and simultaneously injected with in vitro cultured donor-specific wt or DEREG Treg. Diphtheria toxin was injected four weeks after BM transplantation. Two and six weeks after toxin injection, administered DEREG (i.e. Foxp3-eGFP expressing) Treg were no longer detected in spleen, BM, lymph nodes, and PBMC ( Fig. 1G ). These results were confirmed using an experimental setup in which administered DEREG Treg could be traced using the allelic marker Thy1.2. Again, upon administration of DTx we observed a very efficient depletion of administered Treg (Fig. S1 ). Injection of diphtheria toxin, therefore, very efficiently depleted administered DEREG Treg.
Administered Treg are required for induction, but not maintenance, of tolerance to MHC mismatched BM allografts
We next assessed if persistence of administered Treg is required for maintenance of tolerance. Wt B6 mice were preconditioned, grafted with CBA BM, and simultaneously injected with donor-specific DEREG Treg. Mice injected with diphtheria toxin at one week after BM grafting did not develop hematopoietic chimerism ( Fig. 2A ). This effect was due neither to a non-specific effect of the toxin (mice injected with wt Treg and treated with toxin developed chimerism, not shown), nor to an intrinsic defect of DEREG Treg (mice injected with DEREG Treg but not treated with toxin developed chimerism, Fig. 2A ). Therefore, administered Treg are required during the initial phases of tolerance induction. These data also confirmed that injection of diphtheria toxin efficiently depleted injected DEREG Treg. We next performed similar experiments but injected diphtheria toxin at two or four weeks after BM grafting and Treg injection. In both cases, hematopoietic chimerism developed normally and persisted for at least 100 days (Figs. 2B and C). No significant difference in For personal use only. on November 1, 2017. by guest www.bloodjournal.org From chimerism was observed between the groups injected with wt or DEREG Treg, treated or not with diphtheria toxin. It therefore appears that, two weeks after transplantation, administered Treg are no longer required for maintenance of tolerance to the BM allograft.
After depletion of administered Treg, tolerance to BM allografts appears maintained by deletion of donor-specific T cells, not by host Treg
We then assessed which mechanisms were involved in the tolerance to BM allografts that persisted despite depletion of administered Treg. First, we wished to investigate what happens to donor-specific T lymphocytes. To track such cells, we chose to use DBA/2 donors. These mice present a large number of mammary tumor virus-encoded superantigens by their I-E d MHC class II molecules. T cells expressing several TCR Vβ segments, among which Vβ3, Vβ5, Vβ6, but not Vβ4 and Vβ14, recognize these superantigens 23 .
Preconditioned B6 (Thy1.2) mice were grafted with T cell-depleted DBA/2 BM and injected with donor-specific B6 Thy1.1 Treg. The TCR Vβ repertoire of host (i.e. Thy1.2 + H-2K b+ ) T cells was analyzed in spleen and thymus of these chimeras. In sublethally irradiated B6 mice that received a DBA/2 BM in absence of Treg, and that therefore rapidly rejected the allograft, the TCR Vβ repertoire in the spleen did not change very much during the 28-day follow-up period and was similar to that observed in B6 B6 control chimeras (Fig. 3A) . In contrast, in B6 mice that had received a DBA/2 BM allograft and donor-specific Treg, and that therefore accepted the allograft and became chimeric, superantigen-specific TCR Vβ3, 5, and 6expressing CD4 + T cells gradually disappeared and reached levels found in DBA/2 DBA/2 control chimeras by 28 days (Fig. 3A) . Similar results were obtained for the thymus (Fig. 3B ).
The representation of CD4 + T cells expressing Vβ4 (Fig. 3A, B) and Vβ14 (not shown), which do not recognize donor-encoded superantigens, was similar in spleen and thymus of all four types of chimeras studied. Peripheral and central deletion of donor-specific CD4 + T cells, therefore, was gradually established in the chimeras and most surely contributed to the maintenance of tolerance after depletion of administered Treg.
We also investigated if host Treg played a role in the maintenance of tolerance to the BM allograft after depletion of administered Treg. To this end, we preconditioned B6 DEREG hosts and grafted them with DBA/2 BM co-administered with donor-specific DEREG Treg.
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Rapid reconstitution of newly developing Treg avoids autoimmune pathology 22 . As expected, depletion of administered plus host Treg (but not host Treg only, Fig. S2 ) at one week after reconstitution led to rejection of the BM allograft (i.e. in DEREG or wt hosts, Fig. 4A ). Injection of diphtheria toxin at two or four weeks did not lead to rejection of the allografts (Fig. 4B and   C) . These results strongly suggest that host Treg are not involved in the maintenance of tolerance to the BM allografts after depletion of administered Treg.
Persistence of administered Treg is not required for tolerance to skin allografts
We next investigated if persistence of injected Treg was required for maintenance of tolerance to fully allogeneic skin allografts. Wt B6 hosts were preconditioned and reconstituted with DBA/2 BM. DEREG Treg in vitro expanded using (donor x host)F1 (i.e.
[DBA/2 x B6]F1) antigen presenting cells, and therefore specific for directly and indirectly presented alloantigens, were injected with the BM allograft. The thus generated hematopoietic chimeras were grafted with skin from the same donor strain six weeks after BM reconstitution. Grafts were monitored for macroscopic signs of rejection and, if no rejection was observed at the end of the 100-day observation period, they were taken for histological analysis of chronic rejection.
In a first experiment we depleted administered DEREG Treg at ten weeks after BM reconstitution, i.e. at four weeks after skin grafting. During the 100-day observation period we did not observe any macroscopic signs of rejection of the skins (Fig. 5A, B , upper panels).
Histological analysis of the grafts taken at 100 days after skin grafting did not reveal any signs of (chronic) rejection neither (Fig. 5C, upper panels) . Most importantly, we did not see infiltration by mononuclear cells (e.g. macrophages) nor eosinophils, previously observed in chronic rejection of skin allografts 18, 24 . It therefore appears that once the skin allograft is in place, administered Treg are dispensable for maintenance of tolerance.
We next investigated if administered Treg can be depleted before skin grafting. Diphtheria toxin was injected four weeks after BM grafting. Skin from the same donor strain was transplanted two weeks later. During the 100-day observation period no macroscopic signs of rejection were observed in nine out of eleven thus treated mice (Fig. 5A, B , middle panels)
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Host Treg are required for maintenance of skin allograft tolerance.
Central and peripheral deletion, as shown in Fig. 3 , may be involved in the continued protection from chronic rejection of the skin grafts after depletion of injected Treg. We wished to investigate the possibility that host Treg also played a role. B6 DEREG mice were preconditioned and grafted with fully allogeneic DBA/2 BM under cover of DEREG Treg specific for directly and indirectly presented alloantigens. Four weeks later, administered and host Foxp3 + Treg were depleted by injection of diphtheria toxin. Treg-depletion did not change the hematopoietic chimerism ( Fig. 4C ). Two weeks later, DBA/2 skins were transplanted on these chimeras. Grafts were monitored for signs of rejection during a 100-day observation period. Depletion of administered and host Treg in DEREG hosts led to rapid rejection, clearly visible macroscopically ( Fig. 5D right panel) . All grafts on DEREG hosts (five out of five performed) were rejected by 23 days (Fig. 5D, left panel) . Importantly, in all these mice the BM allograft remained in place (Fig. 5E ), and the loss of tolerance was therefore specific for the skin grafts. These data show that host Treg were involved in the continued prevention of skin rejection after depletion of injected Treg. They also demonstrate that DEREG host-Treg are effectively depleted by injection of diphtheria toxin in our experimental model and thus confirm that host Treg are not required for maintenance of the allogeneic BM graft (Fig. 4) .
Combined, our data demonstrate that administered Treg had transmitted their role in the protection of fully allogeneic skin grafts to host Treg that became sufficient for the prevention of chronic rejection.
Host Treg acquire graft-protective capacities similar to that of administered Treg
We previously showed that Treg specific for directly presented donor antigens, i.e. presented by donor MHC molecules, protected skin and heart allografts from acute but not chronic rejection. By contrast, Treg specific for indirectly presented donor antigens, i.e. presented by host MHC molecules, fully prevented chronic rejection 18 . We wished to investigate if the capacity to protect from acute vs. chronic rejection is transmitted from administered to host Treg. As described above, when Treg were specific for directly and indirectly presented donor-antigens, chronic rejection of the skin allografts was prevented, even after depletion of administered Treg (Fig. 5) . We then performed similar experiments but used Treg specific for directly presented alloantigens only. These cells protected skin grafts from acute rejection ( Fig. S3A ) but failed to prevent chronic rejection, thus confirming our previously reported results (Figs. S3B, C). When administered DEREG Treg specific for directly presented donor-antigens were depleted at four weeks post BM grafting, subsequently transplanted skin grafts did not undergo acute rejection but clear signs of chronic rejection were observed (Figs. S3A, B, and C) . It therefore appears that host Treg that protected skin grafts from rejection had acquired the capacity to protect from acute and/or chronic rejection similar to that of administered Treg. In both cases some sparse host Treg could be found inside the skin grafts, suggesting that they may act locally (Fig. S4 ).
Discussion
Previously published data from our laboratory and those of others demonstrated the potential of Treg to induce tolerance to BM, skin and heart allografts in mice [17] [18] [19] 25 . Since injected Treg vanish with time it was important to study if tolerance would persist in their absence. Here we show that injected Treg are essential for the induction of tolerance to BM allografts. By contrast, once tolerance is established, its maintenance does no longer require injected Treg. Mice that had accepted the BM allograft were also tolerant to subsequent skin grafts from the same donor-strain. Injected Treg were not required for acceptance of the skingrafts. However, when injected Treg were depleted, host Treg became critical for skin graftacceptance. It therefore appears that the Treg-mediated immunotherapy against skin graft rejection leads to development of host Treg-mediated tolerance. This mechanism will ensure long-term tolerance to allografts.
Administration of in vitro expanded Treg specific for directly presented donor-antigens leads to permanent protection of BM allografts in mice 16 . Treg-mediated immunotherapy may therefore be envisaged for clinical protocols in which administration of donor stem cells or BM is used to promote tolerance to e.g. kidney allografts. Treg administration may allow for induction of stable hematopoietic chimerism, not detected in the clinical protocols, and thus further improve results 15, 26, 27 . Importantly, our data demonstrate that once the administered Treg had induced tolerance, its maintenance no longer required the presence of these cells.
The long-term persistence of donor-chimerism also indicates that progenitor cells are not rejected. Deletion of donor-specific T cells upon interaction with donor hematopoietic cells, as shown before also by others, probably plays an important role in this persistent, selfsustained, tolerance 28 . Depletion of injected and host Treg at two weeks did not lead to rejection of the BM allograft, despite the presence of some donor-specific T cells. It therefore appears that the latter cells must be anergic 29 or kept under control by regulatory cells not expressing Foxp3. Whatever the explanation, host Foxp3-expressing Treg are not involved.
In our experimental approach, skin grafts are placed after hosts accepted BM grafts. The hematopoietic chimerism alone is insufficient for full tolerance to the skin grafts, consistent with the literature 15 .
Here we show that, in chimeras, administered Treg are not required for
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From acceptance of skin grafts. However, after depletion of injected Treg, host Treg became critically involved in the prevention of skin allograft rejection. Despite the fact that they rejected the skin grafts, recipients in which administered and host Treg were depleted did not reject the BM allograft. T cells specific for tissue-specific antigens, which apparently are not deleted (nor rendered anergic) by hematopoietic cells, therefore presumably rejected the skingrafts. These data confirm that hematopoietic chimerism is insufficient for maintenance of tolerance to allogeneic skin in this model, and that Treg are required. More importantly, our data demonstrate that injected Treg had transferred their tolerogenic role to host Treg.
Transmission of tolerogenic activity from one T-cell population to another one is known as "infectious tolerance" (reviewed in refs. 30, 31) . Allograft-tolerance can be induced by blockade of e.g. CD4 and CD8 co-receptors 32, 33 . Treg from tolerant mice transferred tolerance to a secondary host 34 . When the transferred donor T cells were subsequently depleted, tolerance persisted, and it is thought that host Foxp3 + Treg are involved 35 . Using a very different experimental system, we here directly show that administered Treg had transferred their tolerogenic activity to host Treg. In this report, 'host' Treg are defined as those cells that can be depleted with diphtheria toxin. Even at later time-points, donor BMderived CD4 + T cells represented only a small minority of the total pool of CD4 + T cells in our experimental model (Fig. S5 ), potentially explaining their manifest incapacity to protect the skin allografts.
Treg specific for directly presented donor-antigens protected skin grafts from acute but not from chronic rejection. This observation is consistent with a role for donor-specific antibody (the generation of which requires indirect recognition of donor-antigens) in chronic organ-graft rejection 36 . When administered Treg were depleted, the host Treg involved in protection of the skin grafts from acute rejection still failed to prevent chronic rejection. Injection of Treg with indirect donor-specificity protected from chronic rejection. When these Treg were depleted, the host Treg involved in protection of the skin grafts still prevented chronic rejection. These observations strongly suggested that initially administered and emerging host Treg had similar specificities. This conclusion is consistent with data showing that hemagglutinin-specific Treg can induce Treg with the same specificity from responder T cells in vivo 37 . We postulate that interaction of administered Treg with host cells presenting donor-For personal use only. on November 1, 2017. by guest www.bloodjournal.org From antigens generates a tolerogenic microenvironment in which locally activated conventional T cells differentiate into Treg. This may occur under influence of TGF-β or depletion of essential amino acids, both known to induce Foxp3-expression [37] [38] [39] [40] . Formally we cannot exclude the possibility that host Treg of appropriate specificity may expand or develop in the host thymus under influence of the mixed hematopoietic chimerism. However, hematopoietic chimerism alone fails to prevent chronic rejection, and the latter possibility therefore appears rather unlikely. These issues merit further investigation. This is, to our knowledge, the very first demonstration that Treg can transfer their tolerogenic capacity to other Treg in hematopoietic chimeras in absence of other donortissue. It strongly suggests the involvement of hematopoietic cells, probably dendritic cells, acting in secondary lymphoid organs. In any case, solid donor tissue is not required.
Lastly, in previous reports it was shown that CD4 + CD25 + Foxp3 + Treg could mediate infectious transplantation tolerance 34, 35 . This conclusion was based on adoptive transfer experiments, and the potential implication of other regulatory populations was not assessed.
By in vivo depleting only Foxp3 + Treg we abolished development of tolerance to skin grafts.
Potential other regulatory populations were therefore clearly insufficient for prevention of skin allograft rejection in our experimental model.
In conclusion, experimental Treg-mediated immunotherapy against acute and chronic rejection of skin allografts does not require persistence of administered Treg. A newly emerging host Treg population fully prevents chronic rejection. This mechanism allows for long-term maintenance of tolerance. Administration of in vitro manipulated Treg for the treatment of e.g. graft-rejection or GvHD should turn out to be an attainable goal 41 , and our results indicate that thus induced tolerance should be self-perpetuating.
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